- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00511693
Osteoporosis Coordinator for Low Volume Community Hospitals (ROCKET)
Regional Osteoporosis Coordinator Knowledge Exchange Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A. Background and Rationale. Despite the availability of proven safe and effective treatment options, the majority of patients with low trauma fracture are under-investigated and under-treated, indicating that treatment for osteoporosis after fracture is less than optimal. Most of the published studies on interventions using a coordinator recruited patients from one or a few academic centres or health maintenance organization. However, in Ontario, one-third of fracture patients are treated in non-academic centres and hospitals which have no dedicated osteoporosis fracture clinic coordinator and are underserviced for osteoporosis specialists. It remains unclear whether the impact will be as great for smaller centres where the coordinator function is centralized across multiple centres; hence the need for this trial.
B. Objectives 1. The primary objective is to evaluate if a quality improvement program including physician and patient osteoporosis recommendations from a regional osteoporosis coordinator will increase the proportion of individuals with a low trauma fracture who receive appropriate management for osteoporosis compared to those who receive only falls prevention advice.
2. A secondary objective is to determine if the above program will result in changes in perceived susceptibility, osteoporosis knowledge and use of supplements compared to those who receive only falls prevention advice.
C. Methods. Design: cluster randomized controlled trial (hospitals=cluster site) with the outcome assessors and data analyst blinded to group allocation.
Patient population: patients 40 years old and over (men and women) presenting with a low trauma fracture of the hip, forearm/wrist, rib(s), sternum, thoracic and lumbar spine, shoulder, upper arm, pelvis, lower leg and ankle. Hospitals that treat more than 40 patients/year and have no dedicated fracture clinic coordinator in their Emergency Department/Fracture Clinic will be considered.
Hospital recruitment: out of 63 hospitals 30 will be recruited (15 as intervention and 15 control); 20 patients from each hospital will be identified with the expectation that 10 will consent to the study, for a total sample size of 300 patients.
Intervention: provide evidenced-based recommendations and having a centralized osteoporosis coordinator follow-up with fracture patients and their physicians to provide information about fracture risk and osteoporosis treatment as part of educational outreach, assist with ordering BMD test and arranging consultation to Multidisciplinary Osteoporosis Program (MOP) via telehealth if required. For the control sites the same process will be followed for identifying fracture patients. They will receive educational material and telephone counseling regarding fall prevention and home safety and will be encouraged to visit their family physician.
Data collection. Patients will be identified from NACRS database. Baseline data will be collected by the osteoporosis coordinator. The questionnaire will be similar to "Fracture Clinic OP Screening Program". Follow-up data will be collected by a research assistant who will call consenting patients.
Data Analysis. The analysis of primary and secondary outcome measures will compare the intervention and control groups and will be carried out at the level of the cluster (hospital), based on the standard two-sample t-test with 2(k-1) degrees of freedom, where k is the number of sites in each group (α= 0.05, power=1-β).
D. Future implications. This trial will increase our understanding of how to implement care delivery models in communities in terms of resources, services and patient and provider preferences. At the health system level this trial will have direct relevance to Ontario's Osteoporosis Strategy. The findings will be used by decision-makers to determine if hospitals with no dedicated osteoporosis coordinator should be provided access to a centralized fracture coordinator. At the provider and patient level the trial will increase access to osteoporosis care and treatment utilization, along with awareness and knowledge regarding osteoporosis treatment.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2A2
- Recruiting
- Toronto Rehabilitation Institute
-
Contact:
- Oana S Donescu, MD PhD
- Phone Number: 7884 416 597-3422
- Email: Donescu.Smaranda@TorontoRehab.on.ca
-
Contact:
- Susan B Jaglal, PhD
- Phone Number: 416 978 0315
- Email: susan.jaglal@utoronto.ca
-
Sub-Investigator:
- Gillian Hawker, MD MSc
-
Sub-Investigator:
- Sumit Majumdar, MD
-
Sub-Investigator:
- Dorcas Beaton, PhD
-
Sub-Investigator:
- Suzanne Cadarette, PhD
-
Sub-Investigator:
- Lynn Meadows, PhD
-
Sub-Investigator:
- Alexandra Papaioannou
-
Sub-Investigator:
- Earl Bogoch, MD
-
Sub-Investigator:
- Merrick Zwarenstein, PhD
-
Sub-Investigator:
- Kevin Thorpe, PhD
-
Sub-Investigator:
- Marita Kloseck, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Cluster site (hospital) level: Hospitals with no dedicated osteoporosis coordinator that treat more than 60 patients/year in their Emergency Department and who have a Telehealth studio.
- Patient level: Patients 40 years old and over (men and women) presenting with a low trauma fracture of the hip, forearm and wrist, rib(s), sternum, thoracic and lumbar spine, shoulder and upper arm, pelvis, lower leg and ankle. Subjects without previous medication as well as subjects on osteoporosis medication and presenting with a fracture will be included.
Exclusion Criteria:
- Hospitals that have an Osteoporosis Strategy fracture clinic coordinator
- Fractures associated with major trauma; fractures due to malignancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 1
hospitals randomly allocated to receive physician and patient osteoporosis recommendations from the regional coordinator
|
The regional osteoporosis coordinator will phone fracture patients and counsel them about their risk of osteoporosis, reiterating messages in the print material.
The coordinator will also follow-up with family physicians by phone and send them a patient-specific reminder that informs them that their patient has experienced a fracture and they are at high risk for future fracture.
As part of the reminder, a set of evidence-based recommendations about appropriate BMD testing and treatment based on the recent Canadian guidelines will be included.
If the patient does not have a family physician, the regional osteoporosis coordinator will facilitate referral to the MOP.
|
|
Active Comparator: 2
hospitals randomly allocated to receive falls prevention advice
|
Fracture patients from hospitals receiving falls prevention advice will also be called by the osteoporosis regional coordinator.
The patient will receive educational material and telephone counseling regarding fall prevention.
During the call, patients will be encouraged to visit their family physician for fracture follow-up.
They will not receive counseling or educational materials about osteoporosis at this time.
Patients in the falls prevention group will receive the physician and patient osteoporosis program six months post-fracture.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
proportion of patients from the intervention group as compared to the control group that had "appropriate management" based on a composite of undergoing a BMD test and starting therapy within 6 months of fracture.
Time Frame: 1.5 years
|
1.5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
osteoporosis knowledge, perceived susceptibility, self-efficacy, preventive behaviors
Time Frame: 1.5 years
|
1.5 years
|
|
participants' experience and perceptions of future fracture risk; their understanding of the educational materials and acceptance of recommended treatment plans.
Time Frame: 1.5 years
|
1.5 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Susan B Jaglal PhD, Toronto Rehabilitation Institute, University of Toronto
- Study Director: Oana S Donescu MD PhD, Toronto Rehabilitation Institute, University of Toronto
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TRI REB 07-029
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoporosis
-
Radius Health, Inc.CompletedOsteoporosis | Osteoporosis Risk | Osteoporosis, Postmenopausal | Osteoporosis Fracture | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of Vertebrae | Osteoporosis VertebralUnited States
-
Radius Health, Inc.CompletedOsteoporosis | Age Related Osteoporosis | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of VertebraeUnited States, Poland, Italy
-
National Taiwan University HospitalRecruitingOsteoporosis | Osteoporosis PostmenopausalTaiwan
-
National Taiwan University HospitalNational Taiwan UniversityNot yet recruitingOsteoporosis | Postmenopausal Osteoporosis | Postmenopausal Osteopenia | Primary OsteoporosisTaiwan
-
Hoffmann-La RocheCompletedPostmenopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States, Puerto Rico
-
Appalachian State UniversityNorth Carolina Agriculture & Technical State UniversityCompletedPostmenopausal Osteoporosis | Osteoporosis, OsteopeniaUnited States
-
AmgenCompletedPostmenopausal Osteoporosis (PMO)Japan
-
Hoffmann-La RocheCompletedPostmenopausal OsteoporosisPakistan
-
Hoffmann-La RocheCompletedPostmenopausal OsteoporosisBelgium, Luxembourg, Austria, Greece, Ireland
Clinical Trials on centralized osteoporosis coordinator
-
Institut für Pharmakologie und Präventive MedizinEdwards LifesciencesCompletedAortic Valve StenosisGermany
-
Fujian Academy of Traditional Chinese MedicineCompletedPostmenopausal OsteoporosisChina
-
University of Western Ontario, CanadaJuvenile Diabetes Research FoundationCompleted
-
University of Southern DenmarkCompletedQuality of Life | Polypharmacy | Medication Therapy Management | Medication Review | Potentially Inappropriate MedicationDenmark
-
RTI InternationalRecruitingSickle Cell DiseaseUnited States
-
Université du Québec a MontréalCentre hospitalier de l'Université de Montréal (CHUM); Centre intégré de santé... and other collaboratorsCompletedCommon Mental DisorderCanada
-
Albert Einstein College of MedicineAmerican Cancer Society, Inc.Recruiting
-
Nantes University HospitalUnknownElderly Patients in Complex SituationsFrance
-
Brigham and Women's HospitalNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompletedOsteoporosis | Osteoporosis, PostmenopausalUnited States
-
University of PennsylvaniaNational Psoriasis FoundationActive, not recruitingCardiovascular Diseases | Psoriasis | Psoriatic Arthritis | Psoriatic ConditionsUnited States